Shaman Pharmaceuticals Inc. plans to meet with the FDA this month to discuss an NDA submission for its Provir to treat AIDS-related diarrhea, although the company's Phase III trial of the agent failed to show statistical significance on one of two ways of measuring the primary end point of reduced total daily stool weight.

The company believes the important